Global Patent Index - EP 0979271 A1

EP 0979271 A1 2000-02-16 - VASCULAR ADHESION PROTEIN-1 HAVING AMINE OXIDASE ACTIVITY

Title (en)

VASCULAR ADHESION PROTEIN-1 HAVING AMINE OXIDASE ACTIVITY

Title (de)

VASKULÄRES ADHESIONSPROTEIN-1MIT AMINOXIDASEAKTIVITÄT.

Title (fr)

PROTEINE-1 D'ADHESION VASCULAIRE A ACTIVITE MONOAMINE-OXYDASE

Publication

EP 0979271 A1 (EN)

Application

EP 98922815 A

Priority

  • FI 9800429 W
  • US 86243397 A

Abstract (en)

[origin: WO9853049A1] VAP-1 is an endothelial sialoglycoprotein whose cell surface expression is induced under inflammatory conditions. It has previously been shown to mediate the binding of recirculating lymphocytes to human peripheral lymph node vascular endothelial cells in an L-selectin independent fashion. A VAP-1 cDNA has been purified and shown to encode a type II transmembrane protein of 84.6 KD with a single transmembrane domain located at the very N-terminal end of the molecule. VAP-1 exists, in vivo, predominantly as a dimer of 170-180 KD. Six potential N-linked glycosylation sites are located in the extracellular domain, as are three putative O-glycosylation sites. VAP-1 has no significant similarity to any currently known adhesion molecules but has significant identity to the copper-containing amine oxidase family. Enzyme assays have defined VAP-1 as a membrane-bound amine oxidase. Thus, VAP-1 is a new type of adhesion molecule with dual functions. With the appropriate glycosylation, and in the correct inflammatory setting, VAP-1 expression on the lumenal endothelial cell surface in locations mediating lymphocyte adhesion allows it to function as an adhesion receptor involved in a novel mechanism of lymphocyte homing. Its primary function in other locations may depend on its inherent amine oxidase activity.

IPC 1-7 (main, further and additional classification)

C12N 9/06; C07K 14/435

IPC 8 full level (invention and additional information)

C12N 15/09 (2006.01); C07K 14/435 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 9/06 (2006.01); C12P 21/02 (2006.01); G01N 33/68 (2006.01)

CPC (invention and additional information)

C12N 9/0022 (2013.01); C07K 14/705 (2013.01)

Citation (search report)

See references of WO 9853049A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9853049 A1 19981126; AU 742098 B2 20011220; AU 7531498 A 19981211; CA 2289903 A1 19981126; CN 1269829 A 20001011; EP 0979271 A1 20000216; HU 0002234 A2 20001028; HU 0002234 A3 20051128; JP 2001507238 A 20010605; NO 995725 A 19991122; NO 995725 D0 19991122; NZ 501118 A 20020828; PL 192459 B1 20061031; PL 337004 A1 20000731; RU 2204838 C2 20030520

INPADOC legal status


2005-07-27 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20050119

2003-06-18 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20030502

2001-01-10 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: BIOTIE THERAPIES CORP.

2000-02-16 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 19991028

2000-02-16 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

2000-02-16 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO

- Free text: AL PAYMENT 19991028;LT PAYMENT 19991028;LV PAYMENT 19991028;MK PAYMENT 19991028;RO PAYMENT 19991028;SI PAYMENT 19991028